An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 2nd largest by planned enrollment of the 34 observational ones that give a count, is one of 2 that started in 2023, is one of 34 observational ones, and was the 127th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 547,150 is above the median of 300 across 1,748 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study are:
- Describe the characteristics of all patients initiating sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the modalities of prescriptions of these two drugs and the concomitant treatments.
The secondary objectives are:
All patients in France initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Baseline characteristic: Age
Time frame: up to 5 years
Baseline characteristic: Gender
Time frame: up to 5 years
Baseline characteristic: Region of residence
Time frame: up to 5 years
Baseline characteristic: History of diabetes (date of first Long Term Disease (LTD) status related to diabetes)
Time frame: up to 5 years
Baseline characteristic: Type of diabetes
Time frame: up to 5 years
Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)
Time frame: up to 5 years
Incidence rate of acute cardiovascular atheromatous events during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to first event of acute cardiovascular atheromatous events
Time frame: up to 5 years
Incidence rate of heart failure hospitalization during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to first event of heart failure hospitalization
Time frame: up to 5 years
Incidence rate of deaths all cause during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to death all cause
Time frame: up to 5 years
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.